Gabelli Funds LLC Sells 3,360 Shares of Cencora, Inc. $COR

Gabelli Funds LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,410 shares of the company’s stock after selling 3,360 shares during the quarter. Gabelli Funds LLC’s holdings in Cencora were worth $14,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Cencora by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after acquiring an additional 221,570 shares in the last quarter. State Street Corp boosted its holdings in Cencora by 9.3% in the third quarter. State Street Corp now owns 9,190,316 shares of the company’s stock worth $2,872,249,000 after acquiring an additional 782,911 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after acquiring an additional 821,098 shares in the last quarter. Boston Partners boosted its holdings in Cencora by 2.0% in the third quarter. Boston Partners now owns 4,509,165 shares of the company’s stock worth $1,409,152,000 after acquiring an additional 89,506 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Cencora by 3.0% in the third quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock worth $1,241,094,000 after acquiring an additional 115,278 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $266.03 on Wednesday. The firm has a market cap of $51.76 billion, a PE ratio of 20.40, a PEG ratio of 1.21 and a beta of 0.64. The firm has a fifty day moving average of $310.87 and a 200 day moving average of $338.24. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to analyst estimates of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, research analysts predict that Cencora, Inc. will post 17.76 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s dividend payout ratio is currently 18.40%.

Analyst Ratings Changes

Several brokerages have weighed in on COR. Barclays raised their price target on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Robert W. Baird lowered their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. UBS Group raised their price target on Cencora from $410.00 to $412.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a report on Monday, May 4th. Finally, Morgan Stanley set a $342.00 target price on Cencora in a report on Friday, May 8th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.